Boston Scientific Corp. Cut to `Buy' at Volpe,
Princeton, New Jersey, Aug. 9
(Bloomberg Data) -- Boston Scientific Corp. (BSX US) was
downgraded to ``buy'' from ``buy'' by analyst Phillip E.
Nalbone at Volpe, Brown Whelan & Co. The 12-month target
price is $54.00 per share.
(Based on all
comments today looks like street still believes there's
big upside. Still sorry I didn't have ESP and sell at
$47 and buy back at $30-$31!)
Any thoughts on a future tie up, either mutual
product co-promotion or a merger of the two companies?
Both companies have been running up quite nicely
lately (despite BSX's recalls). But I have difficulty
seeing either company become a top dog without the
other. Are there any other players out there that can
link up with either BSX or STJ to enable them to
compete more effectively with Medtronic and Guidant
across their entire product portfolios?
Inside sources indicate that BSC or parts of it
are on the block.
Wouldn't surprise anybody if it
is. Nicholas was forced to step
down and the
recent Baxter addition to the corporate ranks indicates
that this could happen within the next 12 months.
i'll believe it when i see it!
interventional cardiologists are just going to flock and buy a
huge piece of capitol equipment, to operate a medical
device that is still unproven (?)in in-stent restenosis,
without looking at some of the other debulking options
A: the equipment will still collect dust in the
corner of the supplies cupboard
The fiscal year net sales up to the second
quarter = 726 mil.. if taking worse case 0 gain or-120
mil. from the blade device that would mean a 16.5 %
decrease in net sales (this does
not count the 60 mil
that was sold). Assuming the stock started selling in
the 40�s in advance of the news and stock price
reflecting the sales generated, the value of the
would be at $33.40
problem was recognized and I�m sure it had been then, R&D
was already working on the solution if it hasn�t
already been determined and in-house trials are already
under way. (we�re not talking about rebuilding the
entire machine). Then the estimated six months approval
could be over-blown by as much as three months Or 25%
loss if no sales occur
during this period.
Sales of the machine will probable continue in advance
of the final solution, given the
success of the
device before the problem and the assurance of a safer
machine after the solution. Guessing we are most likely
looking at a worse case of a 25 % reduction in sales (
sales during this period)or -30 mil. or equaling 90 mil
in sales. add the 90 mil back into the total sales
then you may see a loss of 6% of sales or a reduction
in share value to $37.60.
Now is this stock over
sold or not? If i�m missing somethig please fill me
I am enriched with my 5,000 I purchased 2weeks
ago at 1.80 p/sh. Have you been able to establish a
message board site with UK/Yahoo or any of the other?
(With all due respect to those that see Biocompatibles
and BSC do not have a interrelationship.)
by the way, excellent call on CTSI.
those admirers who found BSX to be agargain at 30-32.
How do you say...YOW! Have a great weekend.
You asked if the R&D group still is innovative,
yes they are, at least they are in Minneapolis. The
main problem R&D has is management. Once R&D gets a
project they are hounded by management to get it released
fast� first to market isn�t always the best
Innovative people are still there, management just needs to
let them do their jobs.
This too applies for
Marketing as for pushing products out too fast... they
always have to be first to market.
Go to Bloomberg.com or MSN.com for basic info. Go
to msg#3890 for a link to a message board (Motley
Fool - UK) for BII - UK symbol. You can also find info
at Yahoo Business - UK.
The reason you're
having trouble finding info is the stock, over here, is
on the OTC-BB, which many sites (including Yahoo)